Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pain relief.

A H Dickenson1, K Carpenter, R Suzuki

  • 1Department of Pharmacology, University College, London, WC1E 6BT, UK. anthony.dickenson@ucl.ac.uk

Idrugs : the Investigational Drugs Journal
|August 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EELS: Autonomous snake-like robot with task and motion planning capabilities for ice world exploration.

Science robotics·2024
Same author

Durability of COVID-19 vaccine induced T-cell mediated immune responses measured using the QuantiFERON SARS-CoV-2 assay.

Pulmonology·2022
Same author

Central Nervous System Targets: Supraspinal Mechanisms of Analgesia.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2020
Same author

Influence of behavioral traits in the inter-individual variability of nociceptive, emotional and cognitive manifestations of neuropathic pain.

Neuropharmacology·2019
Same author

Characterisation of peripheral and central components of the rat monoiodoacetate model of Osteoarthritis.

Osteoarthritis and cartilage·2019
Same author

An investigation into the noradrenergic and serotonergic contributions of diffuse noxious inhibitory controls in a monoiodoacetate model of osteoarthritis.

Journal of neurophysiology·2018
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

This meeting highlighted novel pain relief strategies, including excitability blockers and new drug targets. Research focused on sodium and calcium channels, glutamate, and cannabinoid receptors for effective pain management.

Area of Science:

  • Pain research
  • Neuroscience
  • Pharmacology

Background:

  • A meeting convened to discuss recent advancements in pain alleviation.
  • Presentations encompassed both fundamental scientific research and clinical studies.
  • The focus was on novel compounds and clinical data for pain management.

Purpose of the Study:

  • To summarize key findings and selected areas of interest from a pain research meeting.
  • To identify promising therapeutic targets and compounds for pain alleviation.
  • To highlight progress in areas such as ion channel blockers, receptor modulators, and enzyme inhibitors.

Main Methods:

  • Selection of key research areas from meeting presentations.
  • Focus on novel disclosed compounds and clinical data.

Related Experiment Videos

  • Categorization of selected topics including ion channel blockers, receptor targets, and enzyme inhibitors.

    • Main Results:

    • Exciting progress in excitability blockers targeting sodium and calcium channels.
    • Advancements in drugs acting on glutamate and cannabinoid receptors.
    • Development of novel opioids, substance P antagonists, and cyclooxygenase (COX)-2 inhibitors.

    Conclusions:

    • Significant advancements were presented in basic science and clinical studies for pain relief.
    • Novel compounds and therapeutic strategies show promise for managing pain.
    • Selected areas like ion channel modulation and receptor targeting represent key future directions in pain management research.